Perifosine, a novel AKT inhibitor [128], was evaluated in a phase I trial combining daily oral doses (50–200 mg) with fractionated radiotherapy in various advanced solid tumors, including NSCLC, bladder cancer, prostate cancer, and esophageal cancer. Here, AKT1 is linked to Familial prostate cancer.